Table 1. Frequencies of FGFR Mutations and Fusions in the United States.
| Cancer Type | Estimated No. | ||
|---|---|---|---|
| Cancer Deaths, 2019 (N = 455 440) | Patients With FGFR Alteration (n = 35 536)a | Patients With FGFR2 or FGFR3 Alterations (n = 17 019)a | |
| Urothelial cancer | 17 670 | 5601 | 4064 |
| Carcinoma of unknown primary site | 45 140 | 3701 | 2708 |
| Non–small cell lung cancer | 142 670 | 7418 | 2140 |
| Pancreatic exocrine cancer | 45 750 | 2150 | 1601 |
| Breast cancer | 42 260 | 7353 | 1310 |
| Endometrial cancer | 12 160 | 1374 | 1216 |
| Colorectal cancer | 52 300 | 2301 | 889 |
| Glioma | 17 760 | 1350 | 746 |
| Head and neck squamous cell cancer | 21 720 | 999 | 586 |
| Gastric or GE junction cancer | 11 140 | 746 | 546 |
| Ovarian cancer | 13 980 | 1202 | 476 |
| Renal cell cancer | 14 770 | 679 | 340 |
| Cholangiocarcinoma | 3960 | 277 | 242 |
| Sarcoma, all | 6930 | 277 | 104 |
| Melanoma | 7230 | 108 | 51 |
Abbreviations: FGFR, fibroblast growth factor receptor gene; GE, gastroesophageal.
a
Based on percentages of FGFR alterations reported in Helsten et al.4